Catheter Precision (NYSEAMERICAN:VTAK) Shares Up 6.8% – Time to Buy?

Shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) were up 6.8% during trading on Friday . The stock traded as high as $0.21 and last traded at $0.21. 879,451 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 5,109,958 shares. The stock had previously closed at $0.1966.

Catheter Precision Stock Performance

The company has a current ratio of 0.19, a quick ratio of 0.18 and a debt-to-equity ratio of 0.19. The stock has a market cap of $3.02 million, a price-to-earnings ratio of -0.03 and a beta of -1.03. The stock’s 50 day moving average is $0.43 and its two-hundred day moving average is $0.87.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($19.00) by $18.08. Catheter Precision had a negative net margin of 656.03% and a negative return on equity of 37.53%. The company had revenue of $1.02 million for the quarter, compared to analyst estimates of $2.00 million.

Hedge Funds Weigh In On Catheter Precision

An institutional investor recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent SEC filing. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.